Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for prevention of migraine after inadequate response to prior preventive therapies
NL-OMON46819Phase 3Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in migraine (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean change in monthly average number of migraine days over 12 weeks. Started Jul 2017; status: active, not recruiting.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON46819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46819.